The University of Chicago Header Logo

Connection

James Wallace to Protein Kinase Inhibitors

Back to Details
This is a "connection" page, showing publications James Wallace has written about Protein Kinase Inhibitors.
James Wallace
Connection Strength
0.070
Protein Kinase Inhibitors
  1. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Jun; 30(3):1211-5.
    View in: PubMed
    Score: 0.070
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.